

# Cancer Symptom Science

## Expert meeting

October 11<sup>th</sup> – 12<sup>th</sup>, 2023


LAUSANNE

Venue:

AGORA Cancer Research Center

Rue du Bugnon 25A

1005 Lausanne, Switzerland



*Unil*  
UNIL | Université de Lausanne  
Faculté de biologie  
et de médecine

**CHUV** Centre hospitalier  
universitaire vaudois

**AGORA**  
PÔLE DE RECHERCHE  
SUR LE CANCER

## Symposium: Wednesday, 11th October 2023


Auditorium Yves Paternot & AGORA Atrium

09:00	<b>Welcome</b>
09:10	<b>Opening Keynote</b> <b>Christine Miaskowski</b> (US) <i>State of the art in symptom and nursing science</i>
09:30	<b>Keynote session I</b> "The 5 W's of Patient-Reported Outcomes: What; Why; hoW; When; Where?" <b>Keynote 1</b> <b>Doris Howell</b> (CA) <i>What are the most appropriate outcomes to link to the evaluation of symptoms? What should be measured and Why?</i> <b>Keynote 2</b> <b>Jo Armes</b> (UK) <i>Methods for collection: How, when, and where? (cross-cutting aspects in PRO; Single or combined tools)</i>
11:00	<b>Coffee break</b> (Atrium)
11:30	<b>Workshop I: Perspectives / Controversies</b> Which PROM is most valid to evaluate symptoms? Moderators: <b>Mary E. Cooley &amp; Sara Colomer-Lahiguera</b> <b>Talk 1</b> <b>Sandy Mitchell</b> (US) <i>PRO-CTCAE: development and applicability versus EORTC</i> <b>Talk 2</b> <b>Pamela Hinds</b> (US) <i>Patient-Reported Outcome Measures in pediatric oncology</i> <b>Talk 3</b> <b>Manuela Eicher</b> (CH) <i>Symptom collection in patients treated with immune-checkpoint inhibitors</i>
12:30	Open discussion
13:00	<b>Lunch break</b> (Atrium)
14:15	<b>Keynote session II</b> Progress on biomarker research in symptom science <b>Keynote 3</b> <b>Carolyn Harris</b> (US) <i>What do different types of biomarkers tell you?</i> <b>Keynote 4</b> <b>Marilyn Hammer</b> (US) <i>Biomarkers on the road to biosignatures – where are we now</i>
15:45	<b>Coffee break</b> (Atrium)
16:15	<b>Workshop II: Perspectives / Controversies</b> Biomarkers in symptom science: Challenges and opportunities Moderators: <b>Manuela Eicher &amp; Rachel Pozzar</b> <b>Talk 4</b> <b>Susan Wesmiller</b> (US) <i>Genomic Underpinnings of Treatment-induced Symptoms in Women with Breast Cancer</i> <b>Talk 5</b> <b>Omar Cauli</b> (ES) <i>Frailty syndrome and peripheral inflammatory markers in prostate cancer</i> <b>Talk 6</b> <b>Sara Colomer-Lahiguera</b> (CH) <i>An exploratory analysis of symptoms and biomarkers in patients treated with immune-checkpoint inhibitors: lessons learned</i>
17:15	Open discussion
17:45	<b>Closing remarks</b>
18:00 onward	<b>Apéritif</b> (Atrium)

Supported by:



**krebsforschung schweiz**  
**recherche suisse contre le cancer**  
**ricerca svizzera contro il cancro**  
**swiss cancer research**



**Organizing committee:**

Dr Sara Colomer-Lahiguera, UNIL, Lausanne, CH  
Prof. Manuela Eicher, UNIL, Lausanne, CH  
Prof. Marilyn Hammer, DFCI, Boston USA  
Prof. Mary Cooley, DFCI, Boston, USA  
Dr Rachel Pozzar, DFCI, Boston USA  
Prof. Christine Miaskowski, UCSF, San Francisco, USA  
Prof. Susan Wesmiller, UPitt, Pittsburgh, USA  
Dr Carolyn Harris, UPitt, Pittsburgh, USA  
Dr Klara Soukup, UNIL, Lausanne, CH

**Contact:**

[Klara.soukup@chuv.ch](mailto:Klara.soukup@chuv.ch)

[Sara.colomer-lahiguera@chuv.ch](mailto:Sara.colomer-lahiguera@chuv.ch)